Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.

Abstract:

:Glioblastoma multiforme (GBM) is a lethal primary malignant brain tumor in adults. R115777 (tipifarnib) is an oral agent with antiproliferative effects, being a potent and selective inhibitor of farnesyltransferase. This multicenter, open-label phase II study was designed to evaluate the efficacy and safety of R115777 given after surgery and prior to radiation in patients with newly diagnosed and residual enhancing GBM. Following surgery, an MRI confirmed the presence of residual enhancing tumor. Patients on enzyme-inducing antiseizure drugs (EIASDs) received 600 mg twice per day, and those not on EIASDs received 300 mg twice per day. One to three monthly cycles of R115777 were administered, and radiation was initiated with progression or after three cycles. A cycle consisted of 3 weeks of continuous R115777 followed by a 1-week rest. MRI was done monthly. The primary end point was overall survival; secondary end points were tumor response rate and toxicity. A total of 28 confirmed GBM patients entered the study; 15 patients (54%) were on EIASDs. The overall median time of survival was 7.7 months. There were no tumor responses. Eight patients (29%) had stable disease as the best response. The study was stopped early due to progression of the disease in 12 patients (48%). A total of 24 patients (85%) were off study before the planned treatment schedule for radiation therapy. R115777 administered prior to radiation therapy in patients with newly diagnosed GBM and residual enhancing disease did not result in any measurable responses or improvement in survival. R115777 administered prior to radiation therapy is not recommended for patients with newly diagnosed GBM.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Lustig R,Mikkelsen T,Lesser G,Grossman S,Ye X,Desideri S,Fisher J,Wright J,New Approaches to Brain Tumor Therapy CNS Consortium.

doi

10.1215/15228517-2008-070

subject

Has Abstract

pub_date

2008-12-01 00:00:00

pages

1004-9

issue

6

eissn

1522-8517

issn

1523-5866

pii

15228517-2008-070

journal_volume

10

pub_type

杂志文章,多中心研究
  • Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation.

    abstract::Background Notch signaling is deregulated in human gliomas and may play a role in their malignancy. However, the role of each Notch receptor in glioma cell differentiation and progression is not clear. We examined the expression pattern of Notch receptors and compared it with differentiation markers in glioma cell lin...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not168

    authors: Dell'albani P,Rodolico M,Pellitteri R,Tricarichi E,Torrisi SA,D'Antoni S,Zappia M,Albanese V,Caltabiano R,Platania N,Aronica E,Catania MV

    更新日期:2014-01-01 00:00:00

  • Akt2 and Akt3 play a pivotal role in malignant gliomas.

    abstract::Akt, one of the major downstream effectors of phosphatidylinositol 3-kinase, is hyper-expressed and activated in a variety of cancers including glioblastoma. However, the expression profiles of the Akt isoforms Akt1/PKBalpha, Akt2/PKBbeta, and Akt3/PKBgamma and their functional roles in malignant glioma are not well u...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nop026

    authors: Mure H,Matsuzaki K,Kitazato KT,Mizobuchi Y,Kuwayama K,Kageji T,Nagahiro S

    更新日期:2010-03-01 00:00:00

  • Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

    abstract::The objective of this study was to evaluate whether longitudinal levels of serum YKL-40 correlate with disease status or survival in adults with gliomas. Patients with histologically confirmed gliomas were eligible for this longitudinal study. Serum samples were collected prospectively and concurrently with MRI scans ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor117

    authors: Iwamoto FM,Hottinger AF,Karimi S,Riedel E,Dantis J,Jahdi M,Panageas KS,Lassman AB,Abrey LE,Fleisher M,DeAngelis LM,Holland EC,Hormigo A

    更新日期:2011-11-01 00:00:00

  • Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).

    abstract:BACKGROUND:Young age is a favorable prognostic factor for patients with glioblastoma multiforme (GBM). We reviewed the outcomes and molecular tumor characteristics of adolescent and young adult patients with GBM treated in 2 Austrian centers. PATIENTS AND METHODS:Data on patients with histologically proven primary GBM...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos283

    authors: Leibetseder A,Ackerl M,Flechl B,Wöhrer A,Widhalm G,Dieckmann K,Kreinecker SS,Pichler J,Hainfellner J,Preusser M,Marosi C

    更新日期:2013-01-01 00:00:00

  • Understanding brain penetrance of anticancer drugs.

    abstract::This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy018

    authors: Levin VA,Ellingson BM

    更新日期:2018-04-09 00:00:00

  • Role of CX3CR1 signaling in malignant transformation of gliomas.

    abstract:BACKGROUND:Chemokine signaling may contribute to progression of low-grade gliomas (LGGs) by altering tumor behavior or impacting the tumor microenvironment. In this study, we investigated the role of CX3C chemokine receptor 1 (CX3CR1) signaling in malignant transformation of LGGs. METHODS:Ninety patients with LGGs wer...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa075

    authors: Lee S,Latha K,Manyam G,Yang Y,Rao A,Rao G

    更新日期:2020-10-14 00:00:00

  • Symptom-based interventions to promote quality survivorship.

    abstract::Survival alone is no longer an adequate outcome for persons with brain tumors; the quality of the survivorship experience should be viewed with equal importance. Symptom management is a significant component of quality survivorship care. Regardless of their histology, brain tumors and therapies used to treat them prod...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy100

    authors: Amidei C

    更新日期:2018-11-09 00:00:00

  • Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases.

    abstract:BACKGROUND:The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT). METHODS:Patients treated with HSRT for intact brain metastases and/or surgical cavities were reviewed ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz144

    authors: Nguyen TK,Sahgal A,Detsky J,Atenafu EG,Myrehaug S,Tseng CL,Husain Z,Heyn C,Maralani P,Ruschin M,Perry J,Soliman H

    更新日期:2020-01-11 00:00:00

  • A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.

    abstract:BACKGROUND:Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults, and its prognosis remains dismal despite intensive research and therapeutic advances. Diagnostic biomarkers would be clinically meaningful to allow for early detection of the tumor and for those cases in which surgery is cont...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not218

    authors: Manterola L,Guruceaga E,Gállego Pérez-Larraya J,González-Huarriz M,Jauregui P,Tejada S,Diez-Valle R,Segura V,Samprón N,Barrena C,Ruiz I,Agirre A,Ayuso A,Rodríguez J,González A,Xipell E,Matheu A,López de Munain A,Tuñón

    更新日期:2014-04-01 00:00:00

  • The molecular profile of microglia under the influence of glioma.

    abstract::Microglia, which contribute substantially to the tumor mass of glioblastoma, have been shown to play an important role in glioma growth and invasion. While a large number of experimental studies on functional attributes of microglia in glioma provide evidence for their tumor-supporting roles, there also exist hints in...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nos116

    authors: Li W,Graeber MB

    更新日期:2012-08-01 00:00:00

  • Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.

    abstract:BACKGROUND:This study aimed to evaluate the prognostic significance of co-polsomy of chromosome 1q and 19p in 1p/19q codeleted oligodendroglial tumors (ODGs). METHODS:In a series of 148 ODGs with 1p/19q deletion, co-polysomy of 1q and 19p was detected by fluorescence in situ hybridization (FISH). Log-rank analysis and...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not092

    authors: Ren X,Jiang H,Cui X,Cui Y,Ma J,Jiang Z,Sui D,Lin S

    更新日期:2013-09-01 00:00:00

  • Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.

    abstract:BACKGROUND:Altered expression of micro(mi)RNAs has been shown to be associated with tumorigenesis and tumor progression. The expression of phosphatase and tensin homolog (PTEN) plays an important role in glioma and is regarded as a prognostic marker of glioma patients. The goal of this study was to investigate the func...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not107

    authors: Wang XR,Luo H,Li HL,Cao L,Wang XF,Yan W,Wang YY,Zhang JX,Jiang T,Kang CS,Liu N,You YP,Chinese Glioma Cooperative Group (CGCG).

    更新日期:2013-11-01 00:00:00

  • Racial differences in primary central nervous system lymphoma incidence and survival rates.

    abstract::To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma (PCNSL), NCI Surveillance, Epidemiology, and End Results (SEER) program data from 1992 to 2002 were queried. Data were substratified by age (20-49 years vs. 50 or above) and race (White, Black,...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-103

    authors: Pulido JS,Vierkant RA,Olson JE,Abrey L,Schiff D,O'Neill BP

    更新日期:2009-06-01 00:00:00

  • Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.

    abstract:BACKGROUND:Meningiomas are the most commonly diagnosed primary intracranial neoplasms. Despite significant advances in modern therapies, the management of malignant meningioma and skull base meningioma remains a challenge. Thus, the development of new treatment modalities is urgently needed for these difficult-to-treat...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not007

    authors: Iwami K,Natsume A,Ohno M,Ikeda H,Mineno J,Nukaya I,Okamoto S,Fujiwara H,Yasukawa M,Shiku H,Wakabayashi T

    更新日期:2013-06-01 00:00:00

  • Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

    abstract:Background:Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and pharmacokinetics of sonidegib in children with relapsed/recurrent tumors followed by a phase II trial in pediatric and adult patients with relapsed medulloblastoma (MB) to assess tumor response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox109

    authors: Kieran MW,Chisholm J,Casanova M,Brandes AA,Aerts I,Bouffet E,Bailey S,Leary S,MacDonald TJ,Mechinaud F,Cohen KJ,Riccardi R,Mason W,Hargrave D,Kalambakas S,Deshpande P,Tai F,Hurh E,Geoerger B

    更新日期:2017-10-19 00:00:00

  • Imaging of brain and brain tumor specimens by time-resolved multiphoton excitation microscopy ex vivo.

    abstract::Multiphoton excitation fluorescent microscopy is a laser-based technology that allows subcellular resolution of native tissues in situ. We have recently applied this technology to the structural and photochemical imaging of cultured glioma cells and experimental gliomas ex vivo. We demonstrated that high microanatomic...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-034

    authors: Kantelhardt SR,Leppert J,Krajewski J,Petkus N,Reusche E,Tronnier VM,Hüttmann G,Giese A

    更新日期:2007-04-01 00:00:00

  • Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.

    abstract:Background:Targeted approaches for treating glioblastoma (GBM) attempted to date have consistently failed, highlighting the imperative for treatment strategies that operate on different mechanistic principles. Bioenergetics deprivation has emerged as an effective therapeutic approach for various tumors. We have previou...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox243

    authors: Park J,Shim JK,Kang JH,Choi J,Chang JH,Kim SY,Kang SG

    更新日期:2018-06-18 00:00:00

  • Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.

    abstract::Angiogenesis plays a key role in glioblastoma biology and antiangiogenic agents are under clinical investigation with promising results. However, the angiogenic profiles of patients with glioblastoma and their clinical significance are not well understood. Here we characterize the serum angiogenic profile of patients ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq170

    authors: Crocker M,Ashley S,Giddings I,Petrik V,Hardcastle A,Aherne W,Pearson A,Bell BA,Zacharoulis S,Papadopoulos MC

    更新日期:2011-01-01 00:00:00

  • A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

    abstract:BACKGROUND:Higher-grade meningiomas (HGMs; World Health Organization grades II and III) pose a clinical problem due to high recurrence rates and the absence of effective therapy. Preclinical development of novel therapeutics requires a disease model that recapitulates the genotype and phenotype of patient HGM. Oncolyti...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/now031

    authors: Nigim F,Esaki S,Hood M,Lelic N,James MF,Ramesh V,Stemmer-Rachamimov A,Cahill DP,Brastianos PK,Rabkin SD,Martuza RL,Wakimoto H

    更新日期:2016-09-01 00:00:00

  • Tailoring neurophysiological strategies with clinical context enhances resection and safety and expands indications in gliomas involving motor pathways.

    abstract:BACKGROUND:Resection of motor pathway gliomas requires the intraoperative recognition of essential cortical-subcortical motor structures. The degree of involvement of motor structures is variable, and increases as result of treatments patients are submitted to. Intraoperative neurophysiology offers various stimulation ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not327

    authors: Bello L,Riva M,Fava E,Ferpozzi V,Castellano A,Raneri F,Pessina F,Bizzi A,Falini A,Cerri G

    更新日期:2014-08-01 00:00:00

  • Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

    abstract::The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast mate...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox175

    authors: Sarkaria JN,Hu LS,Parney IF,Pafundi DH,Brinkmann DH,Laack NN,Giannini C,Burns TC,Kizilbash SH,Laramy JK,Swanson KR,Kaufmann TJ,Brown PD,Agar NYR,Galanis E,Buckner JC,Elmquist WF

    更新日期:2018-01-22 00:00:00

  • Altered brain morphology after focal radiation reveals impact of off-target effects: implications for white matter development and neurogenesis.

    abstract:Background:Children with brain tumors treated with cranial radiation therapy (RT) often exhibit cognitive late effects, commonly associated with reduced white matter (WM) volume and decreased neurogenesis. The impact of radiation damage in particular regions or tissues on brain development as a whole has not been eluci...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox211

    authors: Beera KG,Li YQ,Dazai J,Stewart J,Egan S,Ahmed M,Wong CS,Jaffray DA,Nieman BJ

    更新日期:2018-05-18 00:00:00

  • Brain metastases in melanoma: roles of neurotrophins.

    abstract::Brain metastasis, which occurs in 20% to 40% of all cancer patients, is an important cause of neoplastic morbidity and mortality. Successful invasion into the brain by tumor cells must include attachment to microvessel endothelial cells, penetration through the blood-brain barrier, and, of relevance, a response to bra...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/s115285170300067x

    authors: Denkins Y,Reiland J,Roy M,Sinnappah-Kang ND,Galjour J,Murry BP,Blust J,Aucoin R,Marchetti D

    更新日期:2004-04-01 00:00:00

  • Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced.

    abstract::Histone deacetylase inhibitors that increase histone acetylation on transformed cells are being investigated as unique anticancer drugs. The aim of this investigation was to evaluate an antiproliferative activity of the histone deacetylase inhibitors sodium butyrate (NaBT) and trichostatin A on 5 glioma cell lines, T9...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/4.2.95

    authors: Kamitani H,Taniura S,Watanabe K,Sakamoto M,Watanabe T,Eling T

    更新日期:2002-04-01 00:00:00

  • The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.

    abstract::First-line therapy for patients with glioblastoma multiforme includes treatment with radiation and temozolomide (TMZ), an oral DNA alkylating chemotherapy. Sensitivity of glioma cells to TMZ is dependent on the level of cellular O(6)-methylguanine-DNA methyltransferase (MGMT) repair activity. Several common coding-reg...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-080

    authors: Remington M,Chtchetinin J,Ancheta K,Nghiemphu PL,Cloughesy T,Lai A

    更新日期:2009-02-01 00:00:00

  • Tumor treating fields: a novel treatment modality and its use in brain tumors.

    abstract::Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/now182

    authors: Hottinger AF,Pacheco P,Stupp R

    更新日期:2016-10-01 00:00:00

  • Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.

    abstract:BACKGROUND:Temporal muscle thickness (TMT) was described as a surrogate marker of skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma. METHODS:TMT was analyzed on cranial MR images of 596 patients with progression of glioblastoma after radiochemo...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1093/neuonc/noz131

    authors: Furtner J,Genbrugge E,Gorlia T,Bendszus M,Nowosielski M,Golfinopoulos V,Weller M,van den Bent MJ,Wick W,Preusser M

    更新日期:2019-12-17 00:00:00

  • Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

    abstract::Development of model systems that recapitulate the molecular heterogeneity observed among glioblastoma multiforme (GBM) tumors will expedite the testing of targeted molecular therapeutic strategies for GBM treatment. In this study, we profiled DNA copy number and mRNA expression in 21 independent GBM tumor lines maint...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-113

    authors: Hodgson JG,Yeh RF,Ray A,Wang NJ,Smirnov I,Yu M,Hariono S,Silber J,Feiler HS,Gray JW,Spellman PT,Vandenberg SR,Berger MS,James CD

    更新日期:2009-10-01 00:00:00

  • ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.

    abstract::Glioma is the most common adult primary brain tumor. Its most malignant form, glioblastoma multiforme (GBM), is almost invariably fatal, due in part to the intrinsic resistance of GBM to radiation- and chemotherapy-induced apoptosis. We analyzed B-cell leukemia-2 (Bcl-2) anti-apoptotic proteins in GBM and found myeloi...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor119

    authors: Day BW,Stringer BW,Spanevello MD,Charmsaz S,Jamieson PR,Ensbey KS,Carter JC,Cox JM,Ellis VJ,Brown CL,Walker DG,Inglis PL,Allan S,Reynolds BA,Lickliter JD,Boyd AW

    更新日期:2011-11-01 00:00:00

  • Treatment of medulloblastoma with a modified measles virus.

    abstract::Although treatment of medulloblastoma has improved, at least 30% of patients with this tumor die of progressive disease. Unfortunately, many of the children who survive suffer long-term treatment-related morbidity. Previous studies have demonstrated the efficacy of using oncolytic viruses to eradicate brain tumors. Th...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq057

    authors: Studebaker AW,Kreofsky CR,Pierson CR,Russell SJ,Galanis E,Raffel C

    更新日期:2010-10-01 00:00:00